Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

RNS60

Nebulized RNS60 will be administered by daily inhalation for 24 weeks.

DRUG

Placebo

Nebulized Placebo will be administered by daily inhalation for 24 weeks.

All Listed Sponsors

lead

Revalesio Corporation

INDUSTRY